Treatment of atrial fibrillation in hypertrophic cardiomyopathy

Anadolu Kardiyoloji Dergisi

Volumn 6, Issue SUPPL. 2, 2006, Pages 44-48

  Hematpour, Khashayar ^a   Steinberg, Jonathan S ^a  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

Author keywords

Ablation; Atrial fibrillation; Cardiomyopathy; Hypertrophy; Pulmonary vein

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DISOPYRAMIDE; DOFETILIDE; FLECAINIDE; PROPAFENONE; SOTALOL; WARFARIN;

ANTICOAGULANT THERAPY; ARTICLE; ARTIFICIAL HEART PACEMAKER; BLEEDING; BRADYCARDIA; BRAIN DISEASE; CARDIOVERSION; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DIASTOLIC DYSFUNCTION; DISEASE CONTROL; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG INDICATION; HEART ATRIUM FIBRILLATION; HEART ATRIUM PACING; HEART SURGERY; HUMAN; HYPERTENSION; HYPERTROPHIC CARDIOMYOPATHY; MEDICAL DECISION MAKING; NONHUMAN; PATHOGENESIS; PULMONARY VEIN; QUALITY OF LIFE; RADIOFREQUENCY ABLATION; SINUS RHYTHM; SUPRAVENTRICULAR TACHYCARDIA; UNSPECIFIED SIDE EFFECT; VEIN DIAMETER;

ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CARDIOMYOPATHY, HYPERTROPHIC; CATHETER ABLATION; HUMANS;

EID: 33846274208     PISSN: 13028723     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Circulation 1995; 92:785-9.
2. Robinson K, Frenneaux MP, Stockins B, Karatasakis G, Poloniecki JD, McKenna WJ. Atrial fibrillation in hypertrophic cardiomyopathy: A longitudinal study. J Am Coll Cardiol 1990; 15:1279-85.
3. Cecchi F, Olivotto I, Montereggi A, Santoro G, Dolara A, Maron BJ. Hypertrophic cardiomyopathy in Tuscany: Clinical course and outcome in an unselected regional population. J Am Coll Cardiol 1995; 26:1529-36.
4. Luchsinger JA, Steinberg JS. Resolution of cardiomyopathy after ablation of atrial flutter. J Am Coll Cardiol 1998; 32:205-10.
5. Kay GN, Ellenbogen KA, Giudici M, Redfield MM, Jenkins LS, Mianulli M, et al. The ablate and pace trial: A prospective study of catheter ablation of the AV conduction system and permanent pacemaker implantation for treatment of atrial fibrillation. J Inter Card Electro 1998; 2:121-35.
6. Feinberg WM, Cornell ES, Nightingale SD, Pearce LA, Tracy RP, Hart RG, et al. Relationship between prothrombin activation fragment F1.2 and international normalized ratio in patients with atrial fibrillation. Stroke Prevention in Atrial Fibrillation Investigators. Stroke 1997; 28: 1101-6.
7. Fuster V, Ryden LE, Asinger RW, Cannom DS, Crijns HJ, Frye RL, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary: A report of the American college of cardiology/American heart association task force on practice guidelines and the European society of cardiology committee for practice guidelines and policy conferences developed in collaboration with the North American society of pacing and electrophysiology. J Am Coll Cardiol 2001; 38: 1231-65.
8. Olivotto, I, Cecchi, F, Casey, SA, Dolara A, Traverse JH, Maron BJ. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation 2001; 104:2517-24.
9. Hamer ME, Blumenthal JA, McCarthy EA, Phillips BG, Pritchett EL. Quality of life assessment in patients with paroxysmal atrial fibrillation of paroxysmal supraventricular tachycardia. Am J Cardiol 1994; 74:826-9
10. Steinberg JS, Sadaniantz A, Kron J, Krahn A, Denny DM, Daubert J, et al. The AFFIRM First Antiarrhythmic Drug Substudy Investigators. Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug. J Am Coll Cardiol 2003;42:20-9.
11. Khairallah F, Ezzedine R, Ganz LI, London B, Saba S. Epidemiology and determinants of outcome of admissions for atrial fibrillation in the United States from 1996 to 2001. Am J Cardiol 2004; 94: 500-4.
12. Falk RH. Atrial fibrillation. N Engl J Med 2001;344:1067-78.
13. Kozhevnikov DO, Yamamoto K, Robotis D, Restivo M, El-Sherif N. Electrophysiological mechanism of enhanced susceptibility of hypertrophied heart to acquired torsade de pointes arrhythmias: Tridimensional mapping of activation and recovery patterns. Circulation 2002;105:1128-34.
14. Sherrid MV, Barac I, McKenna WJ, Elliot PM, Dickie S, Chojnowska L, et al. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2005; 45:1251-8.
15. Steinberg JS, Sadaniantz A, Kron J, Krahn A, Denny DM, Daubert J, et al. Analysis of cause-specific mortality in the atrial fibrillation follow-up investigation of rhythm management (AFFIRM) study. Circulation 2004;109:1973-80.
16. Herweg B, Sichrovsky T, Polosajian L, Vloka M, Rozenshtein A, Steinberg JS. Anatomic substrate, procedural results, and clinical outcome of ultrasound-guided left atrial-pulmonary vein disconnection for treatment of atrial fibrillation. Am J Cardiol 2005;95:871-5.
17. Herweg B, Sichrovsky T, Polosajian L, Rozenshtein A, Steinberg JS. Hypertension and hypertensive heart disease are associated with increased ostial pulmonary vein diameter. J Cardiovasc Electrophysiol 2005; 16: 2-5.
18. Herweg B, Sichrowsky T, Polosajian L, Rozenshtein A, Steinberg JS: Pulmonary vein diameter is increased in patients with paroxysmal atrial fibrillation compared to aged matched controls. J Am Coll Cardiol 2002;39 (Suppl):116A (abstr.)
19. Ommen SR, Maron BJ, Olivotto I, Maron MS, Cecchi F, Betocchi S, et al. Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2005;46:470-6.
20. Schonbeck MH, Brunner-La Rocca HP, Vogt PR, Lachat ML, Jenni R, Hess OM, et al. Long term follow up in hypertrophic obstructive cardiomyopathy after septal myectomy. Ann Thorac Surg 1998;65:1207-14.